Enter inventor name

Joachim Brendel

This inventor holds 55 USPTO granted patents and 9 EPO patents, primarily in Pharmaceutical Chemistry (CPC class 5641). Top assignees: Hoechst Aktiengesellschaft, Aventis Pharma Deutschland, Gmbh, Sanofi. Active years: 1994-2017.

USPTO Granted Patents = 55

% Patents Active = 72.7

EPO Patents = 9 (Patent Applications = 2)

Average Co-Inventor Count = 4.8

ph-index = 10

Forward Citations = 313(Granted Patents)

Forward Citations (Not Self Cited) = 303(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Vilbel, DE (1998)
Bad Vibel, DE (2000 - 2014)
Bad Vilbel, DE (1998 - 2015)
Frankfurt-am-Main, DE (1994 - 2017)

Company Filing History:

19 out of 6,705

Hoechst Aktiengesellschaft

patents

14 out of 330

Aventis Pharma Deutschland, Gmbh

Sanofi-A Ventis Deutschland Gmbh

patents

5. 4 out of 18

Hoechst Marion Roussel Deutschland Gmbh

Cassella Aktiengesellschaft

patents

Years Active: 1994-2017

Loading Chart...

Areas of Expertise:

Isoquinolone Derivatives

Anthranilamides

Substituted Heterocycles

Pharmaceutical Preparations

Medicaments

Cycloalkylamines

Biphenyl Carboxamides

Sulfonamide Compounds

Fused Ring Compounds

Nitrogen-Containing Compounds

55 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9598410 - Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them (2017-03-21),

2. 9127001 - Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them (2015-09-08),

3. 8796458 - Cyclohexylamine isoquinolone derivatives (2014-08-05),

4. 8742116 - Cycloalkylamine substituted isoquinolone derivatives (2014-06-03),

5. 8609691 - Cyclohexylamin isoquinolone derivatives (2013-12-17),

6. 8461144 - Substituted isoquinoline and isoquinolinone derivatives (2013-06-11),

7. 8278294 - Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase (2012-10-02),

8. 8188117 - Piperidinyl-substituted isoquinolone derivatives (2012-05-29),

9. 8106099 - Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias (2012-01-31),

10. 8044074 - Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them (2011-10-25),

11. 7982045 - 2'-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them (2011-07-19),

12. 7825264 - Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them (2010-11-02),

13. 7514582 - 2'-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them (2009-04-07),

14. 7332608 - Anthranilamides and methods of their use (2008-02-19),

15. 7235690 - Anthranilamides and methods of their use (2007-06-26),

Certainly! Here is the article about inventor Joachim Brendel:

Title: Innovator Spotlight: Joachim Brendel, Pioneering Medicinal Chemist from Bad Vilbel, DE

Introduction:

Joachim Brendel, a prolific inventor hailing from Bad Vilbel, Germany, is a distinguished figure in the field of medicinal chemistry, with a remarkable portfolio of 53 patents to his name. His groundbreaking work has significantly impacted the pharmaceutical industry, particularly in the realm of cardiovascular health.

Latest Patents:

Among his latest patents is the development of Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines. These compounds, as outlined in formula (I), exhibit specific interactions with the TASK-1 potassium channel. Brendel's invention showcases their efficacy in treating and preventing atrial arrhythmias, such as atrial fibrillation and atrial flutter, making notable strides in cardiac care.

Career Highlights:

Throughout his illustrious career, Joachim Brendel has lent his expertise to renowned companies such as Hoechst Aktiengesellschaft and Aventis Pharma Deutschland, Gmbh. His innovative approach to medicinal chemistry has not only garnered recognition but has also translated into tangible advancements in pharmaceutical research and development.

Collaborations:

Brendel's collaborative spirit is evident in his partnerships with esteemed colleagues like Hans Jochen Lang and Heinz-Werner Kleemann. Together, they have contributed to the collective knowledge of the field, fostering a culture of innovation and excellence.

Conclusion:

In conclusion, Joachim Brendel stands as a testament to the power of innovation and dedication in driving progress within the realm of medicinal chemistry. His pioneering work serves as an inspiration to aspiring inventors and underscores the transformative potential of groundbreaking research in improving global healthcare outcomes.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]